The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
We care for animals
Boehringer Ingelheim Animal Health delivers leading solutions to prevent, treat and cure animal diseases. In any segment we compete in, we want to provide innovative solutions to address unmet medical needs. We are driven by the wish to improve animal welfare as an integral part of a healthy future for mankind.
Prevention and treatment of mastitis – a welfare issue
Vaccines for the protection of farm animals are a main focus of Boehringer Ingelheim’s animal health business activities. Technological progress has significantly enabled Boehringer Ingelheim to generate vaccines with better and more predictable efficacy. This includes the integration of sophisticated molecular biology and the decoding of the genome of target pathogens.
Boehringer Ingelheim Animal Health also focuses on the treatment of animals, appropriate therapeutic intervention at the very onset of an emerging case of mastitis is of paramount importance in the successful therapy of mastitis in cattle. Offering solutions to our customers which help reducing pain clearly reflects Boehringer Ingelheim Animal Health´s long-term commitment to improving the health and well-being of farm animals.